Alemtuzumab (Lemtrada)


Alemtuzumab is a disease modifying therapy (DMT) used to treat highly active relapsing remitting multiple sclerosis (RRMS) and rapidly evolving severe RRMS.

DMTs are treatments for people with multiple sclerosis (MS) that can help change the course of your MS by reducing the number of relapses and slowing down the buildup of disability in the long term.

You take alemtuzumab through a drip into a vein (intravenous infusion) in 2 treatment courses, 12 months apart.

The brand available on the NHS is called Lemtrada.

On this page, we look at who can take alemtuzumab, how it works, its benefits and possible side effects.

Can I take alemtuzumab (Lemtrada) for my MS?

Disease modifying therapies (DMTs) are offered to people with active relapsing multiple sclerosis.

Alemtuzumab is used for treating adults with highly active relapsing remitting multiple sclerosis (RRMS) and rapidly evolving severe RRMS.

  • Highly active RRMS is when you continue to experience disease activity (relapses and/or new, active or enlarging lesions on an MRI scan) despite treatment with another DMT.
  • Rapidly evolving severe RRMS is when you have had two or more relapses in the previous year and have disease activity (new, active or enlarging lesions) on an MRI scan.

Your MS team will assess whether alemtuzumab is suitable for you and whether you meet the NHS criteria for treatment (NHS England).

Alemtuzumab can only be prescribed by a neurologist.

We have information about other DMTs for treating relapsing remitting MS and progressive MS.

How does alemtuzumab (Lemtrada) work?

In MS, immune cells (lymphocytes or white blood cells) enter the brain and spinal cord (central nervous system) and mistakenly attack the protective covering around your nerves (myelin).

Alemtuzumab works by attaching to and destroying the immune cells which are involved when your immune system attacks myelin. This limits nerve damage caused by MS. It is thought that the immune cells that grow back after treatment with alemtuzumab do not cause damage to nerves.

White blood cells help your body fight infections. Because alemtuzumab reduces the amount of white blood cells in your bloodstream, it affects your body’s immune responses and increases your risk of infections.

How effective is alemtuzumab (Lemtrada) for treating MS?

While disease modifying therapies (DMTs) cannot cure MS, they have several benefits, such as reducing the number of relapses you may have.

The DMTs for treating relapsing remitting MS (RRMS) are grouped according to how effective they are (efficacy) at reducing the number of relapses you may have.

The therapies are described as:

  • moderately effective therapies – these reduce relapses by up to 50%
  • highly effective therapies – these reduce relapses by more than 50%.

Alemtuzumab is considered a highly effective therapy. In clinical trials, people taking alemtuzumab had 49% to 55% fewer relapses than people taking beta interferon (Rebif). Fewer people on alemtuzumab had new, active or enlarging lesions on an MRI scan than those taking Rebif. Alemtuzumab also reduced brain shrinkage (atrophy) by 40% and reduced the risk of disability progression by 42%.

Read the research on alemtuzumab (Lemtrada)

Alemtuzumab has been approved for use on the NHS since 2014. Evidence for the effectiveness of alemtuzumab has come from two large clinical trials.

CARE-MS I – 2012 – Lemtrada compared to beta interferon, Rebif

This 2-year study compared Lemtrada and Rebif in 581 people with relapsing remitting MS in the first few years after diagnosis. These people had not been treated with a disease modifying therapy (DMT) before. Lemtrada reduced relapses by 55% when compared to Rebif. There was no significant difference in disease progression between the two groups.

Read more about the CARE-MS I clinical trial (PubMed).

CARE-MS II – 2012 – Lemtrada compared to beta interferon, Rebif

This 2-year study compared Lemtrada and Rebif in 667 people who had had at least 1 relapse while taking a disease modifying therapy (DMT). Lemtrada reduced relapses by 49% compared to Rebif. The risk of disease progression was also reduced by 42% compared to Rebif. 20% of the Rebif group showed an increase in disability compared to 13% of the Lemtrada group.

Read more about the CARE-MS II clinical trial (PubMed).

Read more about how medicines are developed.

Who can and cannot take alemtuzumab (Lemtrada)?

Before you start taking alemtuzumab, your MS team will discuss the benefits and possible risks of the therapy with you. Together, you will decide if the benefits outweigh any potential risks based on your circumstances. We have more information about starting a disease modifying therapy (DMT) and things to consider.

Alemtuzumab is not suitable for some people. It is important that you tell your MS team if you have any health issues or are taking other medicines.

Alemtuzumab will not be recommended for you if you have, or have had, certain health issues or conditions, such as:

  • other autoimmune conditions
  • history of stroke
  • history of heart attack or chest pain
  • history of bleeding disorders or problems with your blood clotting  
  • uncontrolled high blood pressure
  • serious infection
  • HIV (human immunodeficiency virus) (NHS.UK).

It will also not be recommended if you are allergic to alemtuzumab or any of the other ingredients it contains.

Other health issues your MS team may consider when deciding if alemtuzumab is suitable for you include:

If you have any of the above and alemtuzumab is prescribed for you, you may need additional monitoring during treatment.

Let your neurologist know if:

You are taking or have recently taken other prescribed or unprescribed medicines, vitamins or supplements.

You can find out more about health issues to consider before you start taking alemtuzumab in the Patient Information Leaflet (EMC).

Alemtuzumab (Lemtrada) and conception, pregnancy and breastfeeding

If you're considering taking alemtuzumab or any other disease modifying therapy (DMT), your MS team will proactively discuss family planning and the possibility of pregnancy with you where appropriate.

It is not known if alemtuzumab could harm an unborn baby. It is therefore recommended that you use effective contraception during each treatment course and for 4 months after.

If you have been treated with alemtuzumab and you are considering trying to conceive, your MS team can advise you on when it would be safe for you to start trying for a baby.

If you become pregnant while taking alemtuzumab, tell your MS team straightaway.

It is possible that alemtuzumab may transfer into breastmilk. It is therefore recommended that you do not breastfeed during each treatment course and for 4 months after.

Treatment with alemtuzumab increases your risk of developing certain autoimmune conditions in the years after treatment. These could potentially occur during pregnancy and may affect both you and your baby. It is therefore recommended that regular blood and urine tests are continued through pregnancy.

Tests before starting alemtuzumab (Lemtrada)

Before starting alemtuzumab, you will have:

  • a blood test to measure blood cell counts (NHS.UK)
  • blood and urine tests to check your liver, kidney and thyroid function
  • an MRI scan
  • blood pressure and heart rate checks.

You should also be tested for immunity against the virus that causes chickenpox and be offered the chickenpox vaccine (NHS.UK) if you have not previously been exposed to the virus. Having live vaccines is not recommended if you are taking Lemtrada, so you should consider having any vaccines you need for work or travel at least 6 weeks before you start Lemtrada.

How do I take alemtuzumab (Lemtrada)?

You are given alemtuzumab through a drip into a vein (intravenous infusion). It's given as 2 treatment courses.

  • For the first course, you have an infusion once a day for 5 days in a row.
  • The second course is given 12 months later. You have an infusion once a day for 3 days in a row.

Each infusion takes 4 hours. You will be monitored for 2 hours after each infusion.

You will usually be admitted as an inpatient and stay in hospital for each full treatment course. Alternatively, you may have the option of coming into the hospital each day for your infusion and then going home (day case).

Most people do not need additional treatment courses of alemtuzumab. However, if you have signs of MS activity after 2 courses, your MS team may advise having a third course.

Medicines given before or during treatment to reduce side effects

Before starting treatment with alemtuzumab, you will be given medicines to reduce your risk of certain side effects.

You will be given steroids (corticosteroids) immediately before your infusion for the first 3 days on any treatment course. You may also be given antihistamines and/or paracetamol before your infusions. These treatments reduce your risk of infusion-related reactions.

You will be given an antiviral medicine to reduce your risk of herpes infections like cold sores. You should take this from the first day of your treatment course and continue taking it for 1 month.

Side effects of alemtuzumab (Lemtrada)

All medicines, including disease modifying therapies (DMTs), can potentially cause side effects.

Your MS team will discuss potential side effects of the treatment with you and help you understand your risk. They will also tell you how to manage and report any side effects.

Very common side effects (may affect more than 1 in 10 people) of alemtuzumab include:

  • infusion reactions – symptoms include heart rate changes, headache, rash, fever, hives, flushing and nausea during the infusion or within 24 hours of an infusion
  • infections – colds and sinus infections, urinary tract infections and cold sores
  • decrease in white blood cells
  • thyroid problems such as overactive thyroid (NHS.UK) or underactive thyroid (NHS.UK).

Infusion-associated reactions are the most common side effect with alemtuzumab. In most cases they are mild. You’ll be given medicine before to reduce these reactions.

Common side effects (may affect up to 1 in 10 people) of alemtuzumab include:

  • infections – ear infection, flu, pneumonia and shingles
  • muscle and joint pain
  • changes to liver test results
  • altered sensations like burning, prickling or numbness
  • heartburn
  • immune thrombocytopenic purpura (ITP) – a serious bleeding disorder caused by a low level of blood platelets which stops blood from clotting.

Serious side effects

Some side effects of alemtuzumab can potentially be serious. Your MS team will monitor you regularly for early signs of serious side effects.

Treatment with alemtuzumab may increase your risk of developing certain autoimmune conditions. These can happen months or years after treatment.

Thyroid disorders

In some people, the immune system mistakenly attacks the cells of the thyroid gland, affecting its ability to make and control certain hormones. Symptoms may include unexplained weight loss or weight gain, excessive sweating, feeling cold and tiredness.

Immune thrombocytopenic purpura (ITP)

This is a serious disorder that stops your blood clotting. Symptoms may include small spots on your skin that are red, pink or purple, bruising easily and bleeding from cuts that is harder to stop than usual.

Kidney problems

Sometimes alemtuzumab can cause damage to the kidneys. Symptoms may include blood in your urine (or urine that is red or tea-coloured) and swelling in your legs or feet.

Although potentially serious, these conditions are treatable when they’re caught early.

Speak to your GP or MS team straightaway if:

You experience any of the symptoms associated with the autoimmune conditions listed above.

For a full list of possible autoimmune conditions and their early symptoms, see the Patient Guide for alemtuzumab (EMC) (PDF, 291KB).

Alemtuzumab may also increase your risk of serious infections. To reduce your risk of listeria infection (NHS.UK) (a bacterial infection caused by eating contaminated foods), you should avoid eating uncooked or undercooked meats, soft cheeses and unpasteurised dairy products for 2 weeks before treatment, during treatment and for at least 1 month after treatment.

Cases of a serious brain infection called progressive multifocal leukoencephalopathy (PML) have been reported in people taking alemtuzumab, however this is rare. When you start taking alemtuzumab you will be informed of the early signs of PML. Symptoms of PML can be similar to an MS relapse. If you notice any new or worsening symptoms, you should report them to your MS team straightaway.

Rarely, alemtuzumab can cause serious disorders affecting the heart and blood vessels which may happen shortly after an infusion.

For a full list of side effects, see the Patient Information Leaflet for alemtuzumab (EMC).

You can report side effects through the Yellow Card scheme. Reporting side effects can make a big difference to other people using the same medicine as you.

Can I have vaccinations while on alemtuzumab (Lemtrada)?

People with MS are generally encouraged to have vaccinations which are part of the national vaccinations programme (NHS.UK). Where possible, your MS team will advise you to get relevant vaccinations before you start taking a disease modifying therapy (DMT).

If you've not started treatment with alemtuzumab yet, it's recommended that any vaccines are given at least 6 weeks before treatment starts. This is to make sure your immune system builds up a good response to the vaccines.

If you've started treatment with alemtuzumab, inactivated (non-live) vaccines are considered safe for you to have. It's possible that your body's response to vaccines may be slightly reduced but they still provide a good level of protection.

Live vaccines are not recommended for people on alemtuzumab. This is because there is a small potential risk of developing vaccine-related infections.

Monitoring while on alemtuzumab (Lemtrada)

During infusions of alemtuzumab, your blood pressure and heart rate will be checked every hour. You will also be observed for 2 hours after an infusion. You will have a blood test immediately after the infusion on days 3 and 5 of the first treatment course and on day 3 of any further courses to check platelets in your blood.

Once you’ve started treatment with alemtuzumab, you will have monthly blood tests to check your blood cell counts and the function of your liver and kidneys. You will also have thyroid function tests every 3 months. These tests should be done for 4 years after your last infusion. This is because of the serious nature of potential delayed side effects. These tests will be done at your GP surgery or a hospital clinic, depending on local practice.

If you have unexplained bruising while on treatment with alemtuzumab, speak to your MS team as you may need to have additional blood tests.

It is recommended that women on alemtuzumab have cervical screening (NHS.UK) once a year.

You will likely have regular MRI scans to check your disease modifying therapy (DMT) is working effectively. Your neurologist will advise how often you should have one. They may recommend having an MRI scan 3 to 6 months after starting treatment, then once a year after this to check for MS activity. However, the frequency can vary between MS teams and MRI scans may be done less often than this.

Find out more

References
National Institute for Health and Care Excellence (NICE).
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis.
Technology appraisal guidance TA312 (May 2014, updated May 2024).
Full guideline (link is external)
Scottish Medicines Consortium (SMC).
Advice: alemtuzumab (Lemtrada) – July 2014.
Full guideline (link is external)
Cohen JA, et al.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Lancet 2012;380:1819–28.
Summary (link is external)
Coles AJ, et al.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Lancet 2012;380:1829–39.
Summary (link is external)
Rashid W, et al.
Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance.
Practical Neurology 2025;25(1):18–24.
Full article (link is external)
NHS England.
Treatment Algorithm for Multiple Sclerosis Disease-Modifying Therapies.
NHS England (June 2026).
Full article (link is external)
Sanofi.
Patient information leaflet: LEMTRADA 12 mg concentrate for solution for infusion.
PIL (EMC) (link is external)
Sanofi.
Summary of product characteristics: LEMTRADA 12 mg concentrate for solution for infusion.
SPC (EMC) (link is external)
Sanofi.
Lemtrada (alemtuzumab) – Patient Guide – Risk Minimisation Information for Patients.
Full guide (link is external)
Mullan G, et al.
UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.
Multiple Sclerosis Journal 2026;32(9):885–896.
Full paper (link is external)
Otero-Romero S, et al.
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
Multiple Sclerosis 2023;29(8):904–925.
Full article (link is external)

About this information

This information has been developed by the MS Trust Health Information team. Our team produces accurate evidence-based information to help you navigate your every day – working alongside health professionals. We would like to thank the following health professionals for checking the clinical accuracy of this information:

  • Hollie Bamford, MS Nurse Specialist, East Suffolk and North Essex NHS Foundation Trust
  • Leanne Cave, Lead Pharmacist for Neurology, University Hospitals Dorset, NHS Foundation Trust
  • Victoria Wallace, Consultant Neurologist, Kingston and Richmond NHS Foundation Trust and St George's University Hospitals NHS Foundation Trust.
On this page

Print this page
Share this page